Admitted local publications that cite Editorial Comment to “Primary Resistance to Immune Checkpoint Inhibitor Combination Therapy in Metastatic Renal Cell Carcinoma: Focus on Nivolumab Plus Ipilimumab”.
No admitted local citation edges point to this work yet.
Cited by — Editorial Comment to “Primary Resistance to Immune Checkpoint Inhibitor Combination Therapy in Metastatic Renal Cell Carcinoma: Focus on Nivolumab Plus Ipilimumab” | ResearchHub - ResearchHub
